What it sells
The first Agentic platform for Oncology
Business model breakdown
Buyer: who owns the budget?
UnverifiedOncology departments, radiology and clinical trial teams at hospitals (buyer role not stated).
Trigger: what makes them buy now?
UnverifiedManual CT segmentation and lesion measurement is slow and inconsistent in oncology workflows.
Workflow: what inputs become what output?
Upload CT scans; AI performs body composition/sarcopenia quantification, tumor lesion sizing and target vs non-target lesion classification, replacing manual segmentation.
Distribution: how it reaches customers
Demo-led ("Book a demo"); works with hospitals in US and worldwide and partnerships.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Fall 2025 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.